Reproduce/metastasis of new therapy for immunotherapy for cervical cancer!Chinese scholars study the top of the ASCO stage

*For medical professionals for reading reference

Professor Wang Jing of Hunan Cancer Hospital explores the standard treatment plan for cervical cancer immunomies.

Cervical cancer has the highest incidence in three major gynecological malignant tumors. Although the maturity of screening technology and the use of HPV vaccines can make early detection of cervical cancer and have better treatment effect, early patients with about 10%, 28%-64%of middle and advanced patients will recur and metastasize. After recurrence, the optional treatment method is limited.

In 2022, at the American Clinical Oncology Society (ASCO), Professor Wang Jing of Hunan Cancer Hospital, Professor Wang Jing, studied the "A Study of AK104 (An ANTI-PD1 and Anti-CTLA4 Bispecific Antibody)) Combined with Standard the Fired Pires , Recurren, or Metastatic Cervical Cancer (R/M CC). .] "Clinical Science Symposium. "Medical Tumor Channel" invited Professor Wang Jing to share the cutting -edge progress of cervical cancer immunotherapy.

Scan the QR code below to get more tumor cutting -edge information

- END -